The added value of karyotype in predicting the need for therapy in chronic lymphocytic leukemia with 13q deletion

Affiliations

¹ Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
² Hematology and Clinical Immunology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy.

Annalisa Martines et al. Hematol Oncol. 2023 Dec.

. 2023 Dec;41(5):951-953.

doi: 10.1002/hon.3201. Epub 2023 Jul 3.

¹ Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
² Hematology and Clinical Immunology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy.

No abstract available

References

1. Condoluci A, Terzi di Bergamo L, Langerbeins P, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020;135(21):1859-1869. https://doi.org/10.1182/blood.2019003453
1. Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping. Leukemia. 2007;21(12):2442-2451. https://doi.org/10.1038/sj.leu.2404935
1. Baliakas P, Moysiadis T, Hadzidimitriou A, et al. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. Haematologica. 2019;104(2):360-369. https://doi.org/10.3324/haematol.2018.195032
1. Hernández-Sánchez M, Kotaskova J, Rodríguez AE, et al. CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase. Leukemia. 2019;33(2):518-558. https://doi.org/10.1038/s41375-018-0255-1
1. Del Giudice I, Rigolin GM, Raponi S, et al. Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile. Leukemia. 2018;32(2):543-546. https://doi.org/10.1038/leu.2017.292